Item 8.01 Other Events.
On December 7, 2021, Bellicum Pharmaceuticals, Inc. (the "Company"), closed its
previously disclosed private placement of pre-funded warrants to purchase an
aggregate of 20,559,210 shares of its common stock and accompanying warrants to
purchase an aggregate of 2,055,920 shares of common stock, for gross proceeds of
approximately $35.0 million, before deducting placement agent commissions and
offering expenses payable by the Company.
Taking into account the proceeds from the private placement and certain other
recent developments, the Company believes that, as of the date of this filing,
it satisfies the minimum $2.5 million stockholders' equity requirement for
continued listing on The Nasdaq Capital Market and, as a result, now satisfies
the applicable requirements for continued listing on The Nasdaq Capital Market.
The Company is awaiting a formal compliance determination from the Nasdaq
Listing Qualifications Staff and will provide an update upon receipt of such
determination.
The Company's determination of stockholders' equity is based on estimates and
information available to it as of the date hereof, is not a comprehensive
statement of its financial results or position as of or for the quarter ended
December 31, 2021, and has not been audited, reviewed or compiled by its
independent registered public accounting firm. The Company's financial closing
procedures for the quarter ended December 31, 2021, are not yet complete and, as
a result, stockholders' equity upon completion of its closing procedures may
vary from this preliminary estimate, and any such difference may be material.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses